首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1373367

全球血液篩檢市場 - 2023-2030

Global Blood Screening Market - 2023-2030

出版日期: 2023年10月18日 | 出版商:

DataM Intelligence | 英文 185 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

進行血液篩檢測試以識別感染跡象，以阻止受污染的血液和血液成分用於臨床使用。進行血液篩檢測試是為了檢測沒有任何疾病症狀的人的潛在健康障礙或疾病。

血液篩檢策略旨在確保血液單位的安全，但不應用於通知捐血者反應性檢測結果。血液篩檢測試中使用了多種技術，包括次世代定序、核酸檢測和 ELISA。

市場動態

擴大進行血液篩檢測試

對血液樣本進行血液篩檢測試，以提供有價值的資訊並診斷特定的醫療狀況。血液篩檢測試產品數量的增加是市場成長的重要動力。此外，許多重要公司透過推出新的血液篩檢測試和試劑盒，在市場的進步中發揮重要作用。

例如，2023 年 10 月，Delfi Diagnostics 推出了基於血液的肺癌篩檢測試。它的目的是提供一種更方便的檢測方法，並且能夠覆蓋比目前標準更多的人。

此外，Quest Diagnostics 於2023 年8 月在美國推出了針對阿茲海默症的AD-Detect 檢測，使其成為第一個可供消費者購買和評估阿茲海默症的潛在風險的血液生物標記檢測。

此外，全球血液篩檢市場受到捐血量增加等多種因素的推動，預計傳染病發病率的增加將在預測期內推動市場。

血液篩檢設備的嚴格法規核准和高成本

嚴格的監管要求可能會減緩新血液篩檢技術或測試的批准和採用。此外，與血液篩檢設備相關的高成本可能會阻礙市場成長。

儀器
- 直接購買
- 租購
試劑和試劑盒
- NAT 試劑和試劑盒
  - 標準和控制
  - 標記和檢測試劑
  - 酶和聚合酶
  - 探針和引子
  - 緩衝液、核苷酸和溶液
- ELISA 試劑和試劑盒
  - 綴合物（抗原或抗體綴合成酶）
  - 免疫吸附劑
  - 控制
  - 基材
  - 樣品稀釋劑和清洗溶液
  - 其他試劑

第 8 章：按技術

新一代定序 (NGS)
新一代定序 (NGS)
- 即時聚合酶鍊式反應 (PCR)
- 轉錄介導的擴增 (TMA)
酵素連結免疫吸附測定法 (ELISA)
- ELISA，依平台
  - 螢光免疫分析 (FIA)
  - 化學發光免疫分析 (CLIA)
  - 比色免疫分析 (CI)
- ELISA，依世代
  - 第一代 ELISA
  - 第二代ELISA
  - 第三代ELISA
  - 第四代及以上
蛋白質印跡分析
快速測試
其他

第 9 章：最終用戶

醫院
血庫
其他

第 10 章：按地區

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 歐洲其他地區
南美洲
- 巴西
- 阿根廷
- 南美洲其他地區
亞太
- 中國
- 印度
- 日本
- 澳洲
- 亞太其他地區
中東和非洲

第 11 章：競爭格局

競爭場景
市場定位/佔有率分析
併購分析

第 12 章：公司簡介

Bio-Rad Laboratories, Inc.

公司簡介
產品組合和描述
財務概覽
主要進展

Grifols
Abbott Laboratories
F. Hoffmann-La Roche
Siemens Healthineers
Biomerieux
Thermo Fisher Scientific, Inc.
Ortho Clinical Diagnostics, Inc.
Becton, Dickinson, and Company
Beckman Coulter (Danaher Corporation)

第 13 章：附錄

簡介目錄

Product Code: CD1618

Overview

Blood screening tests are performed to identify infection signs in order to stop the distribution of contaminated blood and blood components for clinical use. A blood screening test is done to detect potential health disorders or diseases in people who do not have any symptoms of the disease.

Blood screening strategies are designed to assure the safety of blood units, but should not be used for notifying blood donors of reactive test results. Various technologies are used in blood screening tests which include next-generation sequencing, nucleic acid tests, and ELISA.

Market Dynamics

Increasing launches of blood screening tests

Blood screening tests are performed on a blood sample to provide valuable information and diagnose specific medical conditions. The increasing number of product launches for blood screening tests acts as a significant driver for market growth. Also, many significant companies play a major role in the advancements of the market by launching new blood screening tests and kits.

For instance, in October 2023, Delfi Diagnostics launched a blood-based lung cancer screening test. It aims to provide a more convenient detection method and one that's capable of reaching a greater number of people than the current standard.

Additionally, in August 2023, Quest Diagnostics introduced its AD-Detect test for Alzheimer's disease in the United States by making it the first blood-based biomarker test available for consumers to purchase and assess the potential risks of developing Alzheimer's disease.

Furthermore, the global blood screening market is driven by various factors like rising blood donations, and an increase in the incidence of infectious diseases is expected to drive the market in the forecast period.

The stringent regulatory approvals and high cost of blood screening equipment

Stringent regulatory requirements can slow the approval and adoption of new blood screening technologies or tests. Also, the high cost associated with blood screening equipment can hamper the market growth.

Segment Analysis

The global blood screening market is segmented based on product type, technology, end users, and region.

Reagents and kits accounted for approximately 48.4% of the market share

The anti-A, anti-B, and anti-A, B reagents are used in the red blood cell determination of the ABO blood group. They are used to determine the absence or presence of erythrocytic antigens A or B on the surface of human red blood cells. Reagents and kits are expected to hold the largest market share over the period forecast owing to the high requirement for reagents, kits, and product launches.

For instance, in June 2023, Sysmex launched an assay kit to identify Amyloid Beta (AB) accumulation in the brain that causes Alzheimer's disease by using a small amount of blood.

Additionally, in July 2021, Ortho Clinical Diagnostics launched its VITROS Immunodiagnostic Products IL-6 Reagent Pack which is the latest addition to Ortho's VITROS Critical Care blood screening menu.

Geographical Analysis

North America is expected to hold a significant position in the global blood screening market share

The global blood screening market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.

North America has maintained a significant market proportion due to factors such as the rising blood transfusion rates, and product launches, this trend is anticipated to continue throughout the forecast period.

For instance, according to the American Red Cross, in the United States, an estimated 10,000 units of plasma, roughly 7,000 units of platelets, and 36,000 units of red blood cells are needed per day. In the United States, more than 21 million blood components are transfused annually.

Additionally, in September 2023, Oxford BioDynamics, Plc. Launched its 94% accurate EpiSwitch prostate screening blood test for men with prostate cancer risk.

COVID-19 Impact Analysis:

The COVID-19 pandemic has had a significant impact on the global blood screening market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, device launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the blood screening market is expected to be moderately affected over the forecast period.

Competitive Landscape

The major global players in the market include: Bio-Rad Laboratories, Inc., Grifols S.A, Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, Biomerieux, Thermo Fisher Scientific, Inc., Ortho Clinical Diagnostics, Inc., Becton, Dickinson, and Company, Beckman Coulter (Danaher Corporation). Among others.

Key Developments

In March 2023, H.U. Group Holdings Inc. introduced the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE G immunoassay systems. These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of Neurofilament light (NfL) in human cerebrospinal fluid (CSF) and plasma.
In June 2021, Grail launched the Galleri blood screening test which is a multi-cancer screening capable of detecting many cancers.

Why Purchase the Report?

To visualize the global blood screening market segmentation based on product type, technology, end users and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of blood screening market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global blood screening market report would provide approximately 61 tables, 58 figures, and 185 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Technology
3.3. Snippet by End User
3.4. Snippet by Region

4. Market Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing launches of blood screening tests
  - 4.1.1.2.
- 4.1.2. Restraints
  - 4.1.2.1. The stringent regulatory approvals and high cost of blood screening equipment
  - 4.1.2.2.
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Instruments*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Outright Purchase
- 7.2.4. Rental Purchase
7.3. Reagents & Kits
- 7.3.1. NAT Reagents & Kits
  - 7.3.1.1. Standards and Controls
  - 7.3.1.2. Labeling and Detection Reagents
  - 7.3.1.3. Enzymes and Polymerases
  - 7.3.1.4. Probes and Primers
  - 7.3.1.5. Buffers, Nucleotides, and Solutions
- 7.3.2. ELISA Reagents & Kits
  - 7.3.2.1. conjugates (Antigen Or Antibody-Conjugated Enzyme)
  - 7.3.2.2. Immunosorbents
  - 7.3.2.3. Controls
  - 7.3.2.4. Substrates
  - 7.3.2.5. Sample Diluents and Wash Solutions
  - 7.3.2.6. Other Reagents

8. By Technology

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.1.2. Market Attractiveness Index, By Technology
8.2. Next-Generation Sequencing (NGS) *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Next-Generation Sequencing (NGS)
- 8.3.1. Real-Time Polymerase Chain Reaction (PCR)
- 8.3.2. Transcription-Mediated Amplification (TMA)
8.4. Enzyme-Linked Immunosorbent Assay (ELISA)
- 8.4.1. ELISA, By Platform
  - 8.4.1.1. Fluorescence Immunoassay (FIA)
  - 8.4.1.2. Chemiluminescence Immunoassay (CLIA)
  - 8.4.1.3. Colorimetric Immunoassay (CI)
- 8.4.2. ELISA, By Generation
  - 8.4.2.1. First-Generation ELISA
  - 8.4.2.2. Second-Generation ELISA
  - 8.4.2.3. Third-Generation ELISA
  - 8.4.2.4. Fourth-Generation & Above
8.5. Western Blot Assay
8.6. Rapid Tests
8.7. Others

9. By End Users

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
- 9.1.2. Market Attractiveness Index, By End Users
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Blood Banks
9.4. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. UK
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. Australia
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Bio-Rad Laboratories, Inc.
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Grifols
12.3. Abbott Laboratories
12.4. F. Hoffmann-La Roche
12.5. Siemens Healthineers
12.6. Biomerieux
12.7. Thermo Fisher Scientific, Inc.
12.8. Ortho Clinical Diagnostics, Inc.
12.9. Becton, Dickinson, and Company
12.10. Beckman Coulter (Danaher Corporation)